Through these collaborations, Abbott aims to enable personalised lifestyle and therapy interventions, so people with diabetes can achieve holistic glucose management goals
Abbott has announced new collaborations with key health-tech partners BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly for diabetes management care. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which approximately 6.5mn users can access through PharmEasy and 1MG. The company is focused on maintaining effective glucose level along with remote consultations, diabetes-specific coaching, and dietary plans.
Through these collaborations, Abbott aims to enable personalised lifestyle and therapy interventions, so people with diabetes can achieve holistic glucose management goals.
The pandemic led to the deployment of disruptive technologies in the healthcare industry leading to breakthroughs in patient care. For example, sensor-based monitoring devices and virtual consultations are helping people manage glucose levels at home. Availability of wearable devices such as Abbott’s FreeStyle Libre have enabled patients to continuously monitor glucose levels and provide real time insights to doctors. Abbott has also partnered with BeatO, a digital health platform to launch a holistic, data-based continuous glucose monitoring program for better diabetes management. The program provides users access to targeted diet, help in controlling diabetes and lifestyle counselling from experts based on the data recorded by FreeStyle Libre.
Kalyan Sattaru, General Manager, diabetes care business, Abbott, said, “Continued research and strategic partnerships have simplified and strengthened diabetes management over the years. New diabetes technology has paved the way for precise and informed decision making. Connecting our partner brands’ products with the FreeStyle Libre portfolio will enable users to capture their glucose data easily as part of an integrated system.”
- Advertisement -